Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — FY 2023/24 Earnings Presentation
100 slides from Coloplast A/s Class B's earnings presentation, Nov 5, 2024
Slide 1: Making life easier – Roadshow presentation FY 2023/24
Roadshow presentation FY 2023/24 Making life easier Strive25: Sustainable Growth Leadership Victoria User, Ostomy Care Ostomy Care | Continence Care | Advanced Wound Care | Interventional Urology | Voice and Respiratory Care
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: FY 2023/24 organic growth of 8% and 27% EBIT margin; FY 2024/25 guidance
FY 2023/24 organic growth of 8% and 27% EBIT margin1. FY 2024/25 guidance of 8-9% organic growth and ~28% EBIT margin1 Revenue growth FY 2023/24 highlights Reported revenue (mDKK) Organic growth • Organic growth of 8% (8% in Q4) and reported growth in DKK of 10%. Acquired growth from the Kerecis acq
Slide 4: Strategic highlights from Strive25 – Sustainable growth leadership
Strategic highlights from Strive25 – Sustainable growth leadership Growth Innovation Atos Medical Luja , a new intermittent catheter with a Micro-hole Zone Technology • 11% growth in 2023/24 with solid contributions from both Laryngectomy and Tracheostomy. • Launch of Luja for men in key markets con
Slide 5: FY 2023/24 organic growth of 8%, driven by Chronic Care
FY 2023/24 organic growth of 8%, driven by Chronic Care and double- digit growth in Voice & Respiratory Care and Advanced Wound Care FY 2023/24 revenue by business area FY 2023/24 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growt
Slide 6: Q4 Ostomy Care organic growth of 6%
Q4 Ostomy Care organic growth of 6%, partly held back by baseline in Emerging markets. Broad-based FY 2023/24 organic growth of 7% Ostomy Care performance Q4 and FY 2023/24 highlights • Q4 organic growth was 6% and reported growth was 7%, with solid contribution across regions: 9 8 8 • The US benefi
Slide 7: Continence Care growth of 10% in Q4
Continence Care growth of 10% in Q4 with growth across segments and strong contribution from Luja . FY 2023/24 organic growth of 8% Continence Care performance Q4 and FY 2023/24 highlights • Q4 organic growth was 10%, while reported growth increased by 12% • Growth was broad-based and led by Europe.
Slide 8: Voice & Respiratory Care Q4 organic growth of 12%
Voice & Respiratory Care Q4 organic growth of 12%, driven by both Laryngectomy and Tracheostomy. FY 2023/24 organic growth was 11% Voice & Respiratory Care performance Q4 and FY 2023/24 highlights • Q4 organic growth was 12% and reported growth was 10% • Growth in Laryngectomy was double-digit, driv
Slide 9: Adv. Wound Care grew 10% organically in Q4
Adv. Wound Care grew 10% organically in Q4, driven by Skin Care and 1-month contribution from Kerecis. FY 2023/24 organic growth of 10% Advanced Wound Care performance Q4 and FY 2023/24 highlights* • Q4 organic growth was 10% and reported growth was 33% 51 • Advanced Wound Dressings grew 4%, reflect
Slide 10: Interventional Urology grew 7% in Q4
Interventional Urology grew 7% in Q4, driven by Men’s Health and Endourology. FY 2023/24 organic growth was 5% Interventional Urology performance Q4 and FY 2023/24 highlights • Q4 organic growth was 7% and reported growth was 6% • The Men’s Health and the Endourology businesses were the main growth
Slide 11: FY 2023/24 reported revenue grew 10%
FY 2023/24 reported revenue grew 10% with ~4%-points contribution from Kerecis and ~1%-point negative impact from currencies FY 2023/24 Revenue development (mDKK) FY 2023/24 highlights • Reported revenue increased by DKK 2,530 million or 10% vs. last year. +2,530 • Organic growth was 8% or DKK 1,899
Slide 12: FY 2023/24 reported EBIT margin of 27%
FY 2023/24 reported EBIT margin of 27%1, impacted by ~100 basis points dilution from Kerecis, as expected, and currency headwind FY 2023/24 EBIT margin development before special items (%) FY 2023/24 highlights • Gross margin was 68%, against 67% last year • Positive impact from: ~100 bps contributi
Slide 13: 2023/24 adjusted FCF of DKK 3.9 billion
2023/24 adjusted FCF of DKK 3.9 billion. Operating cash flow impacted by the extraordinary tax payment related to the Atos Medical IP transfer FCF development1 FY 2023/24 highlights • Free cash flow for FY 2023/24 was an inflow of DKK 1,430 million, 98 compared to an outflow of DKK 4,731 million las
Slide 14: FY 2024/25 guidance: organic growth of 8-9%
FY 2024/25 guidance: organic growth of 8-9% and reported EBIT margin before special items of around 28% GUIDANCE 2024/25 GUIDANCE (DKK)* KEY ASSUMPTIONS • Growth across business areas and geographies is expected to be largely in line with the Strive25 expectations, with the exception of China Chroni
Slide 15: Introduction to Coloplast
Making it easier to be yourself Leading intimate healthcare Introduction to Coloplast Theresa | CC user
Slide 16: Coloplast has five business areas with global sales presence
Coloplast has five business areas all with global sales presence Group revenue 2023/24 by segment Group revenue 2023/24 by geography 1 Continence Care 1 32% European Ostomy Care markets 35% 54% Other developed markets 29% DKK 4 DKK 27.0bn 27.0bn Interventional Urology 10% 1 Voice & 5 Emerging market
Slide 17: Coloplast specializes in intimate healthcare needs
Coloplast specializes in intimate healthcare needs Who are our typical users How do we help them? Our brands Ostomy Care People who have had a part of their Adhesive ostomy bags SenSura® Mio digestive or urinary system redirected to an Supporting products Brava® opening in the abdominal wall Contine
Slide 18: The Chronic Care model secures a predictable revenue stream
The Chronic Care model secures a predictable revenue stream and stable revenue growth The chronic care user flow Chronic Care condition New user Installed base of users Stable flow of loyal users Solid reimbursement Coloplast group revenues Revenue (DKK bn) Organic growth (%) 10 8 8 8 8 8 8 7 7 7 7
Slide 19: Intimate healthcare is characterized by stable industry trends
Intimate healthcare is characterized by stable industry trends 01. 01. Demographics Healthcare reforms Growing elderly population Economic restraints drive increases customer base for reimbursement reforms, Coloplast products introduction of tenders, Limiters and lower treatment cost Drivers 02. 02.
Slide 20: Strong market positions in Europe and commercial potential outside Europe
Coloplast has strong market positions in Europe and great commercial potential outside Europe Europe Other developed Emerging Ostomy Continence Voice & Respiratory Interventional Advanced 1 1 1 4 5 X Global market position Care Care Care (Laryngectomy) Urology Wound Care Addressable market 44-48bn 2
Slide 21: Active role in the care continuum addressing unmet needs
We are building a company that plays an active role in the care continuum and addresses unmet needs in the market Macro Trends Impact Commercial model Ageing population Superior, clinically differentiated products Healthcare consumerism Digital transformation Consumer Clinical Data preference prefer
Slide 22: Strive25 strategy supports long-term value creation
Our Strive25 strategy supports continued long- term value creation through revenue and earnings growth Long-term financial guidance 8-10% more than 30% organic growth EBIT margin p.a.1 beyond 2024/252 1 Raised to 8-10%, from previously 7-9%, on July 7 as a result of the acquisition of Kerecis, expec
Slide 23: Strive25 emphasis on environmental performance
With Strive25 we put emphasis on improving our environmental performance, while continuing our ongoing commitments Our mission Making life easier for people with intimate healthcare needs Our 2025 priority Our 2025 priority Improving products Reducing emissions and Packaging 90% of packaging recycla
Slide 24: Yearly incremental investments of up to 2% of revenue
We will continue to support organic growth through yearly incremental investments of up to 2% of revenue in the Strive25 period Key Investment Decision Drivers Key Investment Areas – up to 2% of revenue in incremental OPEX investments Investments made in H1 of Strive25 Continued investments in H2 of
Slide 25: Strive25: M&A plays a bigger role
Strive25: M&A plays a bigger role as we seek to secure long-term growth and value creation options beyond 2025 Opportunity Systematic based screening Large plays Channel expansion Portfolio expansion Early-stage & adjacencies technologies Examples: 2022 US direct-to-consumer TFL Drive DME dealers1 (
Slide 26: Key enablers supporting the commercial model in Chronic Care
We have built key enablers to support the commercial model in our Chronic Care businesses Commercial model Key enablers Coloplast® Care Superior, clinically differentiated products Direct to Consumer Consumer Clinical Direct Businesses preference Data preference Data & Digital tools Payer preference
Slide 27: Direct business in Chronic Care drives improved outcomes
Direct business in Chronic Care serving consumers drives improved outcomes and is a vital component of our growth Direct presence in top 5 markets and strategic rationale Coloplast Consumer presence (incl. patient support programme, Coloplast® Care) Control and continuity 1 of product supply +30 cou
Slide 28: Clinical Performance Programme to tackle users' biggest issues
We have initiated a very ambitious Clinical Performance Programme to tackle the biggest issues users face Continence Care – preventing UTIs remains one of the biggest unmet needs Ostomy Care – Leakage remains the biggest challenge for our users 45 % of users describe UTIs as their greatest challenge
Slide 29: Luja catheter platform with Micro-hole Zone Technology
Luja , our new catheter platform with Micro-hole Zone Technology addresses key UTI risk factors UTI Risk Factor Model1 UTI risk factors addressed by Luja Intermittent General patient catheterisation conditions UTI risk factor: UTI risk factor: Non-hygienic technique Urethral trauma UTI risk factors
Slide 30: Comprehensive clinical program behind Luja
Comprehensive clinical program behind Luja to demonstrate the clinical relevance and difference Pivotal studies 2 multinational pivotal studies2 involving 110+ users demonstrating the impact on key risk factors of UTIs Pilot studies Multicenter, randomised cross 8 studies comparing Luja vs. over tri
Slide 31: Data on Heylo is promising
Data on Heylo is promising. Pivotal clinical study showed improvement in quality of life and a 31% reduction in leakage Pre-pilot study on Heylo Pivotal clinical studies on Heylo Product performance & user experience1 First pivotal clinical study on Heylo4, conducted in Germany showed: Using Heylo s
Slide 32: Inflationary headwind and PPA amortisation impact profitability
Inflationary headwind across cost categories, PPA amortisation related to acquisitions and Kerecis have negatively impacted profitability short-term Gross Profit development, % Cost item % of revenue* • FY 22/23 Gross Profit negatively impacted by inflationary headwind on input costs (raw materials,
Slide 33: Global Operations Plans have delivered significant value since 2008
Global Operations Plans (GOPs) have delivered significant value since 2008, supporting Coloplast’s industry leading profitability 2008 2009 2012 2017 2020 2023-2026 Turn-around GOP1 GOP2/GOP3 GOP4 GOP5 GOP6 Focused Operational Operational Step change Fit for the future Excellence Excellence executio
Slide 34: GOP6 drives efficiency improvements
GOP6 will support Coloplast’s growth agenda and drive continued efficiency improvements to support EBIT margin ambition Optimize footprint Drive efficiencies in procurement • New manufacturing site of 30,000 m2 in Portugal • Company-wide procurement programme initiated, aimed at driving • Portugal s
Slide 35: Global Business Support and IT landscape enables scale
A global Business Support and IT landscape enables Coloplast to scale faster and efficiently and integrate Atos Medical into the Group Global Business Services Global business services handle the majority of all global support % of group processes 100% ~90% 100% 100% IT infrastructure Finance / acco
Slide 36: EBIT margin development drivers
EBIT margin development continues to be a function of growth, scalability, cost discipline and investment activity EBIT margin (%) Illustrative Future drivers of EBIT margin EBIT will be positively impacted by: • Leverage effect on fixed costs e.g. >30% distribution, admin and R&D costs especially d
Slide 37: Continued strong free cash flow development during Strive25
Continued strong development in free cash flow during the Strive25 strategy period Taxation Net working capital CAPEX1 Reported tax rate Net working capital, % of revenue CAPEX DKKm Depreciation and amortisation, % of revenue CAPEX, % of revenue 5% 5% 5% 5% 5% 6% ~5% 5% 4% 5% 4% 4% 4% 25% 26% 25% 23
Slide 38: Attractive cash returns despite investments
We will continue to provide attractive cash returns despite investments in commercial activities and the Atos Medical and Kerecis acquisitions Coloplast cash distribution to investors Highlights • Coloplast returns excess liquidity to shareholders in the Dividends paid out in the year (DKKm) (1) Sha
Slide 39: Stable shareholder returns through value creation levers
In sum, we believe Coloplast can continue to deliver stable shareholder returns through ... Organic growth and EBIT margin Value creation levers 27% • Stable market trends in our Chronic Care business • Innovative product portfolio and new product launches 8% • Strong Coloplast Care retention progra
Slide 40: Introduction to Kerecis
Introduction to Kerecis An emerging category leader in the biologics wound care segment
Slide 41: With Kerecis, Coloplast adds a long-term growth business
With Kerecis, Coloplast adds a long-term growth business, uniquely positioned to support long-term value creation Compelling strategic rational Kerecis financial assumptions Performance of Kerecis • Three-year revenue CAGR of ~30% until FY 2025/26 • Attractive gross margin level, accretive to Colopl
Slide 42: Entering the biologics segment in advanced wound care
We enter the biologics segment, expanding our footprint in the US and transforming our presence in the global advanced wound care market Addressable advanced wound care market by segment Addressable advanced wound care market (advanced dressings and biologics) Gelling Fibers 1 Advanced 4-6 With Kere
Slide 43: Kerecis fish-skin technology platform
Kerecis is transforming wound healing with its clinically differentiated technology platform based on gently processed fish skin Kerecis key business highlights Started in 2009, with headquarters and manufacturing in Iceland Proprietary product platform based on intact fish skin DKK 1,026m Revenue f
Slide 44: Fish skin – uniquely positioned for wound healing in humans
Fish skin – uniquely positioned for wound healing in humans Kerecis fish-skin technology – gently processed, preserving its similarity to human skin Fish Skin for Human Skin* Epidermis Dermis 100 µm 100 µm Advantages of the fish-skin technology: • High resemblance to human skin: similar three-dimens
Slide 45: Compelling clinical evidence with 50+ publications
Comparative RCTs & Second-Degree Burns Difficult Wounds Compelling clinical Prospective Clinical and Excised Full- with Trials Thickness Burns Pain Reduction evidence with 50+ 1. Intact Fish Skin Graft to 1. Staubach et al. J Clin Med 1. T. J. Clasen, E. Libich, M. publications showing Treat Deep Di
Slide 46: Sustained strong growth momentum at Kerecis
Sustained strong growth momentum through proven commercial model and a purpose-driven organisation Kerecis revenue distribution, FY 2023/24 Sustained strong growth through: By wound type: By care setting: By geography: • Continued strong growth in the US across wound types and care settings US • Acc
Slide 47: Introduction to Atos Medical (Voice and Respiratory Care)
Introduction to Atos Medical (Voice and Respiratory Care) The global market leader in laryngectomy Joakim | Provox Life user
Slide 48: Atos Medical leads the attractive chronic laryngectomy market
Atos Medical is the leader in the attractive chronic laryngectomy market, with strong growth and profitability outlook Key market and business highlights Key financial assumptions Laryngectomy Tracheostomy • Organic growth 8-10% Procedures per year ~50,000 ~1,000,000 Organic growth • Laryngectomy: h
Slide 49: Atos improves lives following Total Laryngectomy
Atos improves the lives of patients following Total Laryngectomy procedures A Total Laryngectomy is a non-elective After surgery, a Voice Prosthesis (VP) is inserted by a healthcare professional, and the surgery performed in the advanced stages patient applies the Heat- and Moisture Exchanger (HME)
Slide 50: Untapped potential in the laryngectomy market
There is significant untapped potential in the laryngectomy market today, which we will seek to eliminate The laryngectomy market, DKKbn Low level of market penetration due to: We will eliminate the ‘white space’ by: Lack of clinical standards in existing 01 markets outside of Northern Europe Settin
Slide 51: Tracheostomy patients have similar needs as laryngectomy patients
Tracheostomy patients have similar needs as laryngectomy patients, as they are both breathing through a neck stoma A Tracheostomy is a surgical The Tracheostomy patient journey starts with a cannula insertion, which can be procedure that creates an opening in reversed at any stage the neck for direc
Slide 52: Leading intimate healthcare – Appendices
Leading intimate healthcare Leading intimate healthcare Appendices Laura | IC user
Slide 53: The Coloplast share
The Coloplast share (COLO-B.CO) Holders of A shares and family 1 Danish institutions Foreign institutions Coloplast A/S Coloplast share listed on Nasdaq Copenhagen Other shareholders since 1983 Non-registered shareholders 3.0% ~200.1 billion DKK (~29 billion USD) market 1.0% 5.0% cap @ ~888.2 DKK pe
Slide 54: Capital structure
Capital structure Highlights Net interest-bearing debt Overall policy is that excess liquidity is returned to shareholders through a combination of dividends (paid bi-annually) and 2.5x share buy-backs (expected at DKK 500m per year; no buy- 2.3x 2.4x back in FY 23/24 and FY 24/25). Below 2.0x Inter
Slide 55: Q4 organic growth of 8% by business area and geography
Q4 organic growth of 8%, driven by Continence Care and double-digit growth in Voice & Respiratory Care and Advanced Wound Care Q4 2023/24 revenue by business area Q4 2023/24 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Shar
Slide 56: Q4 reported revenue grew 12%
Q4 reported revenue grew 12% with ~3%-points contribution from the Kerecis acquisition and ~1%-point positive impact from currencies Q4 2023/24 Revenue development (mDKK) Q4 2023/24 highlights • Reported revenue increased by DKK 727 million or 12% vs. last year. • Organic growth was 8% or DKK 510 mi
Slide 57: Q4 reported EBIT margin of 26%
Q4 reported EBIT margin of 26%1, impacted by ~100 basis points dilution from Kerecis, extraordinary cost in the US and currency headwind Q4 2023/24 EBIT margin development before special items (%) Q4 2023/24 highlights • Gross margin was 67%, compared to 66% last year 0.4 -2.4 • Positive impact from
Slide 58: Key value ratios
Key value ratios Profitability drivers Free Cash Flow drivers 33.4 32.6 36.2 36.8 32.3 32.0 31.5 34.6 34.7 31.2 32.4 32.3 31.7 30.1 30.7 29.0 28.7 28.2 26.1 26.3 25.3 23.6 23.4 23.7 4.2 4.1 3.9 4.5 4.6 4.6 5.0 5.2 5.0 5.1 5.0 3.5 3.9 3.8 3.9 3.8 3.6 3.4 18/19 19/20 20/21 21/22 22/23 23/24 18/19 19/2
Slide 59: Revenue development by business area
Coloplast revenue development by business area Ostomy Care Interventional Urology Voice & Respiratory Care1 10 8 7 6 6 19 16 Reported growth 5 4 7 5 6 10 9,546 14 5 10% 11% 8,620 9,024 9 10 7,538 7,841 4 9% -7 -7 2,424 2,674 2,775 1,835 2,097 1,939 2,110 NA NA 1,203 19/20 20/21 21/22 22/23 23/24 19/
Slide 60: Revenue development by geography and total
Coloplast revenue development by geography and total Europe Other Developed Markets1 15 8 6 2 4 21 20 6 8 12 2 4 5 5 6 8 14,750 5 3 6 9 7,746 12,916 13,908 11,261 5,775 6,480 10,820 4,644 4,785 19/20 20/21 21/22 22/23 23/24 19/20 20/21 21/22 22/23 23/24 Emerging Markets Coloplast group2 15 15 14 16
Slide 61: Segment operating profit
Segment operating profit Segment Operating Profit DKKm (Excludes shared/non-allocated costs) Segment Operating Profit Margin (%) Chronic Care Interventional Urology Voice & Respiratory Care1,2 Adv. Wound Dressings Biologics1,3 Ostomy and Continence Care 36 38 58 58 58 58 57 34 34 35 40 40 36 37 38 3
Slide 62: FY 2023/24 PPA amortisation impact on EBIT margin
FY 2023/24 Atos Medical and Kerecis PPA amortisation impact on EBIT margin 32% 3% 29% 28% 1% 27% 27% 1% 0% DKK -34 DKK 311 DKK 140 DKK 839 million million million million FY 2023/24 Special items total1 EBIT margin PPA amortisation2 EBIT margin Amortisation excl. EBITA Depreciation EBITDA EBIT margi
Slide 63: Exchange rate exposure and hedging policy
Exchange rate exposure FY 2023/24 and hedging policy Revenue FX exposure 2023/241) 12 months exposure from 10% initial exchange rate drop1) Other 18% -740 EUR USD -240 34% CNY, JPY, AUD, BRL & ARS 10% -370 GBP -220 HUF 0 13% 150 GBP 25% Revenue (DKKm) EBIT (DKKm) USD Foreign exchange rate guidance f
Slide 64: Healthcare reforms and price pressure expectations
No significant healthcare reforms expected in FY 2023/24. The expectation of long-term price pressure of up to 1% p.a. is unchanged Europe Rest of World • Netherlands: Reimbursement pressure on OC and CC • US: CMS review of coverage for skin substitutes, relating to the • France: Reimbursement press
Slide 65: Coloplast CARE helps increase retention
Coloplast CARE helps us increase retention and improve product compliance We co-develop CARE content with CARE is a personal and “high- Global program with shared local clinicians touch” program infrastructure Advisors available on phone Clinically validated content and call protocol - ERP Website w
Slide 66: Direct-to-Consumer marketing program
With our Direct-to-Consumer marketing program we reach into the community We operate in numerous channels to expose our …and with the reach we get several benefits service and product offering… Introduce innovative products Ensure product accessibility Ensure successful experience 66
Slide 67: Generic model for distribution and reimbursement
The generic model for distribution and reimbursement of our products Prescription & Insurance Product Reimbursement price Prescription & Insurance Payer Distribution Consumer $ Product 67
Slide 68: Interventional Urology revenue at a glance
Interventional Urology revenue is balanced geographically and across the four business areas Interventional Urology at a Glance ~15% market share in global market of DKK 18-20bn market FY 23/24 growing 4-6% annually 10% Coloplast position, FY 23/24 of Coloplast sales Bladder Health & Endourology Men
Slide 69: Interventional Urology business areas and select products
Coloplast Interventional Urology consists of four business areas Men’s Women’s Bladder Health Endourology & Surgery Health Health • Erectile Dysfunction • Stress Urinary Incontinence • Stone Management • Bladder Drainage • Male Incontinence (SUI) • Transurethral • Benign prostatic hyperplasia • Test
Slide 70: Strong presence in Interventional Urology with room to capture share
We have a strong presence in our categories in Interventional Urology but there is room to capture market share 1 Men’s Health Women’s Health Endourology Bladder Health & 1 Surgery Inflatable Penile Male Stress urinary Pelvic organ Prosthesis (IPP) incontinence incontinence prolapse Fragmented Compe
Slide 71: Refined product roadmap in Interventional Urology
We are executing a refined product roadmap in Interventional Urology aligned to Strive25; progress is tracking to key milestones Strategy Description Men’s Health Women’s Health Endourology Projects that address regulatory Cadence of stone Strengthen core requirements, close gaps and maintain IPP En
Slide 72: Portfolio expansions with TFL Drive and Intibia
Portfolio expansions in adjacent segments with TFL Drive and Intibia provide strong growth potential for Interventional Urology Target Adjacencies Target Adjacencies AUS ED OAB BPH AUS POP Core SUI Coloplast Endo Consum- Endo TFL Drive Laser ables • Launched in Q4 2021/22 Prostate • State of the art
Slide 73: Intibia gives option to enter OAB market
With Intibia , Coloplast obtained an option to enter the attractive OAB market worth around 1bn USD. Launch expected in FY 2025/26 Overactive bladder (OAB) market Why Implantable Tibial Nerve Stimulation (ITNS)? Less invasive ITNS complete in single procedure +80m people globally suffer from OAB sym
Slide 74: Wound & Skin Care 2025 strategic plan
The Wound & Skin Care 2025 strategic plan (Advanced Wound Dressings) Expand in the US Win in Europe Lead in China Outgrow market and deliver competitive profitability Reach full 3DFit Selectively potential invest Selectively expand Drive commercial portfolio excellence 74
Slide 75: In US Ostomy Care we continue to win across the patient pathway
In US Ostomy Care we continue to win across the patient pathway We have invested across the care continuum in Strive25 … and are now seeing acute share gains translate into the community US OC patient pathway Bags and plates acute share +7%-pts Acute Post-acute Community 2019 (pre-GPO) H1 23/24 MAT
Slide 76: Awarded access to key GPOs in US Ostomy Care
Coloplast has been awarded access to key GPOs, ensuring a level playing field in ~75% of acute accounts in US Ostomy Care Coloplast has been awarded access to Vizient and Premier, the two largest GPOs in the US Acute members1 Estimated Contract Contract Contract Acute share2 expiry date length type
Slide 77: US Continence Care and hydrophilic catheters
In US Continence Care, we drive the upgrade of the market to hydrophilic catheters and aim to set a new standard of care with Luja We are driving the upgrade to hydrophilic-coated US IC reimbursement categories catheters in the US Hydrophilic catheters as % of Coloplast On 16 August 2024, CMS has is
Slide 78: Sustainability - key priorities and actions
Sustainability - key priorities and actions Improving products Reducing emissions Responsible and packaging operations Why is this a key priority: Why is this a key priority: Why is this a key priority: As a manufacturer of medical products made primarily As a growing company, we are challenged by a
Slide 79: FY 23/24 progress on sustainability ambitions
FY 23/24 progress on key sustainability ambitions Improving products and packaging Reducing emissions Responsible operations 2025 FY FY 2025 FY FY 2025 FY FY Ambition 23/24 22/23 Ambition 23/24 22/23 Ambition 23/24 22/23 100% 2.6 90% 2.0 2.1 Recyclable 74% 74% Scope 1+2 emissions Lost time injury pa
Slide 80: Introducing Ostomy Care
Introducing Key products Ostomy Care • Between 2 and 3 million people live with a stoma globally, ~2/3 in the developed markets • Up to around 300,000 stoma surgeries per year in developed markets and China Disease areas SenSura® Mio in black SenSura® Mio Concave SenSura® Mio Convex SenSura® Mio • C
Slide 81: Ostomy Care Supporting Products
Introducing Key products Ostomy Care Supporting Products Market fundamentals Heylo Brava® Protective Seal Brava® Skin Barrier Brava® Elastic Tape • Market size of DKK 4-5bn Digital leakage notification system Designed for leakage Reducing skin problems Elastic so it follows the • Market growth of 6-
Slide 82: Introducing Continence Care
Introducing Key products Continence Care • Intermittent catheters for management of urinary retention and collecting devices for management of urinary incontinence Luja Intermittent catheter with SpeediCath® Flex Set SpeediCath® Navi SpeediCath® Flex • Around 6 million people live with urinary reten
Slide 83: Introducing Bowel Care
Introducing Key products Bowel Care Market fundamentals • Market size for transanal irrigation of DKK ~1bn • High-single digit market growth Peristeen® Light Peristeen® Plus Peristeen® Transanal Irrigation Transanal Irrigation Transanal Irrigation Disease areas Launched in 2024 Launched in 2021 Laun
Slide 84: Introducing Laryngectomy
Introducing Key products - Laryngectomy Voice & Respiratory Care Provox® Life Laryngectomy Heat and Moisture Exchangers (HMEs) Home Go Night Protect Energy Free hands Disease areas • People that have undergone a total laryngectomy, a typical treatment for advanced Provox® Life laryngeal and hypophar
Slide 85: Introducing Tracheostomy
Introducing Voice & Respiratory Care Tracheostomy Disease areas Key products - Tracheostomy • Performed when the airways are restricted, e.g., during an emergency when the airways are blocked, or when a Portfolio expansion disease or other problem makes normal breathing impossible • Strengthened the
Slide 86: Introducing Interventional Urology
Introducing Key products Interventional Urology • Men’s Health: men with erectile dysfunction. ~25% of men aged 40-70 years old experience moderate to severe erectile dysfunction. • Women’s Health: women with pelvic organ prolapse and stress urinary incontinence. ~50% of women 50- 79 years old repor
Slide 87: Introducing Advanced Wound Dressings
Key products Introducing Advanced Wound Dressings Disease areas Biatain® Silicone Fit Biatain® Silicone Non-Border Biatain® Fiber Biatain® Contact Silicone foam dressing for Silicone foam dressing without a Reinforced gelling fiber. Silicone contact layer. Chronic wounds pressure injury prevention b
Slide 88: Introducing Skin Care
Introducing Key products Skin Care Disease areas • Moisture associated skin damage Sween® EasiCleanse® Bath • Incontinence Broad line of skin care products Disposable bathing wipes • Skin folds & obesity Designed to increase consistency of care Improves patient experience • Prevention of skin impair
Slide 89: US Skin Care at a glance
At a glance US Skin Care US Skin Care market Market Market drivers drivers andand limiters limiters + +AgingAging and obese population and obese population US market size estimated + +CMSCMSValueValue BasedBased Purchasing Purchasing at DKK 5-6bn with 2-4% growth + +Increased focusfocus Increased on
Slide 90: Coloplast organisation: Chronic Care and Strategic Business Units
The Coloplast organisation is divided into Chronic Care and Strategic Business Units, running on shared global business support functions Coloplast Group Chronic Care Strategic Business Unit Advanced Interventional Voice & Ostomy Care Continence Care Biologics (Kerecis) Wound Dressings Urology Respi
Slide 91: The Coloplast Executive Leadership Team
The Coloplast Executive Leadership Team* Kristian Villumsen Anders Lonning-Skovgaard Dorthe Rønnau Allan Rasmussen President, CEO EVP, CFO EVP, People & Culture EVP, Operations With Coloplast since 2008 With Coloplast since 2006 With Coloplast since 2022 With Coloplast since 1992 Nicolai Buhl Anders
Slide 92: Income statement
Income statement DKKm Q4 2022/23 Q4 2023/24 Change FY 2022/23 FY 2023/24 Change Revenue 6,226 6,953 12% 24,500 27,030 10% Gross profit 4,132 4,640 12% 16,328 18,269 12% SG&A costs -2,184 -2,577 18% -8,633 -10,069 17% R&D costs -231 -219 -5% -872 -913 5% Other operating income/expenses -3 -41 nm 22 -
Slide 93: Balance sheet
Balance sheet DKKm 30 Sep 2023 30 Sep 2024 Change Balance, total 48,159 48,073 0% Assets Non-current assets 38,222 37,629 -2% Current assets 9,937 10,444 5% of which: Inventories 3,522 3,672 4% Trade receivables 4,315 4,675 8% Marketable securities, cash, and cash equivalents 911 788 -14% Other rece
Slide 94: Cash flow
Cash flow DKKm FY 2022/23 FY 2023/24 Change EBIT 6,771 7,320 8% Amortisation 334 451 35% Depreciation 735 839 14% Adjustment for other non-cash operating items -220 -92 -58% Change in working capital -893 -1,032 16% Net interest payments -769 -762 -1% Paid tax -1,732 -3,958 129% Cash flow from opera
Slide 95: Manufacturing footprint and COGS categories
Coloplast manufacturing footprint and COGS categories Production by country (Volume)¹ 5% 0% Isafjordur Hungary 10% 0% Costa Rica 3% Hörby China Mørdrup 13% Nieder-Olm Tatabánya US/France Minneapolis Nyirbátor Mankato Porto Sarlat Zhuhai Denmark 70% Atos (SE/DE) Kerecis (Iceland) Costa Rica COGS by c
Slide 96: Production sites
Production sites Hungary China Tatabánya Zhuhai • Continence care products • Ostomy care products • Ostomy care products • Adhesives • Machine building • Continence care products • Number of employees in production: ~750 • Interventional Urology products • Number of employees in production: ~1,650 C
Slide 97: Production sites
Production sites France Sweden Sarlat Hörby • Disposable surgical urology products • Research & Development centre and • Number of employees in production: ~250 manufacturing of laryngectomy products • Number of employees in production: ~120 US Germany Minneapolis Nieder-Olm • Interventional Urology
Slide 98: Coloplast Sponsored Level 1 ADR programme
Coloplast Sponsored Level 1 ADR programme Coloplast Sponsored ADR Programme Benefits of a Coloplast ADR programme to US Investors: • Coloplast has established a sponsored ADR programme in the US, as a Symbol CLPBY service to US investors by offering an alternative way to trade Coloplast shares, whil
Slide 99: Contact Investor Relations
Contact Investor Relations Holtedam 1 DK-3050 Humlebæk Denmark Aleksandra Dimovska Kristine Husted Munk Vice President, Investor Relations Senior Manager, Investor Relations Tel. direct: +45 4911 2458 Tel. direct: +45 4911 3266 Office: +45 4911 1800 Office: +45 4911 1800 dkadim@coloplast.com dkkhu@c
Slide 100: Mission, values and vision
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding